What We're Reading: More on Cigna’s Reviews of Claims
Debbie Day, a former medical director at Cigna, alleges in an interview with ProPublica that the insurer tracked medical director productivity with a dashboard that logged how long the doctors took to review claims. Over the last few years, these metrics have taken a larger role in employee evaluations, with speed of claim review being used to determine raises and bonuses, according to Day. In this story, Cigna said the scores were not used to track the work of individual doctors.
This is a follow-up to a story last year, in which ProPublica reported that Cigna was using an algorithm to automatically deny claims. In this story, Cigna denied that the algorithm was used to reject claims without review.
Cigna has not responded to a request for comment from Formulary Watch.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
